Karl-Erik Andersson to Muscarinic Antagonists
This is a "connection" page, showing publications Karl-Erik Andersson has written about Muscarinic Antagonists.
Connection Strength
5.466
-
Andersson KE. Potential Future Pharmacological Treatment of Bladder Dysfunction. Basic Clin Pharmacol Toxicol. 2016 Oct; 119 Suppl 3:75-85.
Score: 0.469
-
Andersson KE. The use of pharmacotherapy for male patients with urgency and stress incontinence. Curr Opin Urol. 2014 Nov; 24(6):571-7.
Score: 0.425
-
Gratzke C, Andersson KE. a-Blockers and antimuscarinics for male lower urinary tract symptoms: the search goes on. Eur Urol. 2013 Jan; 63(1):166-7; discussion 168.
Score: 0.366
-
Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol. 2011 Aug; 72(2):186-96.
Score: 0.339
-
Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011 Mar; 59(3):377-86.
Score: 0.325
-
Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int. 2010 Jul; 106(2):268-74.
Score: 0.302
-
Füllhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson KE. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. BJU Int. 2010 Jul; 106(2):287-93.
Score: 0.301
-
Andersson KE. Pharmacotherapy of the overactive bladder. Discov Med. 2009 Oct; 8(42):118-24.
Score: 0.299
-
Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009 Jul; 19(4):380-94.
Score: 0.294
-
Andersson KE, Fullhase C, Soler R. Urothelial effects of oral agents for overactive bladder. Curr Urol Rep. 2008 Nov; 9(6):459-64.
Score: 0.281
-
Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stöhr T, Andersson KE. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008 Apr; 101(8):1036-42.
Score: 0.267
-
Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007 Nov; 100(5):987-1006.
Score: 0.262
-
Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int. 2007 Nov; 100(5):1007-14.
Score: 0.262
-
Hedlund P, Streng T, Lee T, Andersson KE. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J Urol. 2007 Jul; 178(1):326-31.
Score: 0.253
-
Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004 Jan; 3(1):46-53.
Score: 0.201
-
Andersson KE. Treatment of the overactive bladder: possible central nervous system drug targets. Urology. 2002 May; 59(5 Suppl 1):18-24.
Score: 0.179
-
Andersson KE. Drug therapy of overactive bladder--what is coming next? Korean J Urol. 2015 Oct; 56(10):673-9.
Score: 0.113
-
Andersson KE. ß3-receptor agonists for overactive bladder--new frontier or more of the same? Curr Urol Rep. 2013 Oct; 14(5):435-41.
Score: 0.099
-
Streng T, Andersson KE, Hedlund P, Gratzke C, Baroni E, D'Ambrosio D, Benigni F. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction. BJU Int. 2012 Jul; 110(2 Pt 2):E125-31.
Score: 0.088
-
Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. BJU Int. 2012 Feb; 109(4):572-80.
Score: 0.085
-
Andersson KE. How many drugs for LUTS due to BPH are too many? J Urol. 2008 Sep; 180(3):811-2.
Score: 0.069
-
Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006 Sep; 98(3):503-7.
Score: 0.060
-
Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006 Jul; 148(5):565-78.
Score: 0.059
-
Takeda H, Yamazaki Y, Igawa Y, Kaidoh K, Akahane S, Miyata H, Nishizawa O, Akahane M, Andersson KE. Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn. 2002; 21(6):558-65.
Score: 0.044
-
Ekman M, Andersson KE, Arner A. Developmental regulation of nerve and receptor mediated contractions of mammalian urinary bladder smooth muscle. Eur J Pharmacol. 2006 Feb 17; 532(1-2):99-106.
Score: 0.015
-
Staskin DR, Wein AJ, Andersson KE, Bauer SB, Blaivas JG, Burgio KL, Cardozo L, Chapple CR, Dmochowski RR, Gupta S, Mostwin JL, Ouslander JG, Weiss JP, King L. Overview consensus statement. Urology. 2002 Nov; 60(5 Suppl 1):1-6.
Score: 0.012